Can I Switch From Mounjaro Injections to Wegovy Tablets? UK Switching Guide

As Wegovy tablets become available in the UK, many patients currently using Mounjaro injections are asking whether they can switch from a weekly tirzepatide injection to a once-daily semaglutide tablet.

Unlike switching from Wegovy injections to Wegovy tablets, there is currently no published manufacturer conversion guide for switching from Mounjaro (tirzepatide) to Wegovy tablets (oral semaglutide).

Because these medicines contain different active ingredients and work differently within the body, any switch should be made under the supervision of a qualified healthcare professional.

At Pharmulous, our prescribing clinicians assess each patient individually to determine the most appropriate treatment plan, starting dose and monitoring strategy.

Interested in switching treatment? View here

Can You Switch from Mounjaro to Wegovy Tablets?

Some patients may be suitable for switching from Mounjaro injections to Wegovy tablets following a clinical assessment.

Common reasons patients consider switching include:

• Long-term treatment planning
• Preference for a daily treatment routine
• Easier medication storage
• Travel convenience
• Needle anxiety
• Preference for tablets over injections

However, because tirzepatide and semaglutide are different medicines, switching is not a direct equivalent change.

Treatment decisions should always consider:

• Current Mounjaro dose
• Weight loss progress
• Side effects experienced
• Medical history
• Other medications
• Individual treatment goals

Mounjaro vs Wegovy Tablets: What's the Difference?

Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors.

Wegovy tablets contain semaglutide, which acts on GLP-1 receptors only.

Both medicines may support weight management by helping to:

• Reduce appetite
• Increase feelings of fullness
• Reduce calorie intake
• Support long-term weight management

However, individual responses can vary significantly.

At the time of writing, there is no published manufacturer conversion guide or MHRA-approved dose equivalence chart for switching from Mounjaro injections to Wegovy tablets.

Because of this, any suggested conversion should be viewed as a clinical starting point rather than a direct equivalent dose.

Patients should be monitored closely after switching to assess:

• Appetite control
• Weight management progress
• Gastrointestinal side effects
• Treatment tolerability
• Overall treatment effectiveness

Suggested Mounjaro to Wegovy Tablet Conversion Guide

The table below outlines the conversion approach currently used by Pharmulous clinicians when considering a switch from Mounjaro injections to Wegovy tablets.

       

Please note, the above conversions are based on clinical experience and prescribing judgement. They are not manufacturer-approved dose equivalents and should not be used without medical supervision.

Patients should generally be established on their current Mounjaro injection dose for at least 4 weeks and be tolerating treatment well before a switch is considered.

When Should I Start Wegovy Tablets After My Last Mounjaro Injection?

The timing of the switch depends on individual clinical circumstances.

In many cases, patients may start Wegovy tablets when their next Mounjaro injection would have been due.

However, treatment timing should always be confirmed by a qualified healthcare professional.

What Should I Expect After Switching?

Some patients notice very little change after switching treatment.

Others may experience temporary differences in:

• Appetite suppression
• Hunger levels
• Satiety
• Weight loss rate
• Gastrointestinal side effects

Because tirzepatide and semaglutide work differently, individual responses can vary.

Close follow-up is particularly important during the first few weeks after switching.

Common Side Effects After Switching

Possible side effects may include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Indigestion
• Abdominal discomfort

These side effects are generally similar to those experienced with other GLP-1 medicines and often improve as the body adjusts to treatment.

Our Clinical Approach at Pharmulous

At Pharmulous, we do not automatically recommend increasing medication doses.

Our clinical approach focuses on using the lowest effective dose that helps patients achieve their weight management goals while minimising side effects.

When patients switch from Mounjaro to Wegovy tablets, our clinicians consider:

• Current treatment response
• Previous side effects
• Weight loss progress
• Long-term treatment goals
• Individual tolerability

Patients switching treatment are encouraged to maintain regular contact with our clinical team so that efficacy and side effects can be reviewed and treatment adjustments made where appropriate.

Need support with switching treatment? Contact the Pharmulous team or complete an online assessment today. 

Key Takeaways

• Any switch should be supervised by a qualified healthcare professional.
• Patients should generally be stable on their current Mounjaro dose for at least 4 weeks before switching.
• Ongoing monitoring is important to assess efficacy and tolerability.
• Pharmulous provides doctor-led assessment and ongoing support throughout the switching process. 

Useful links:

• Wegovy tablets UK
• Oral semaglutide
• Switching from Wegovy injections to Wegovy tablets

References

1. Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 medicines for weight loss and diabetes: what you need to know. Available at: https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know

2. National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity (TA1026). Available at: https://www.nice.org.uk/guidance/ta1026

3. Novo Nordisk. Wegovy Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/13801

4. Eli Lilly. Mounjaro Summary of Product Characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/product/15481

5. The Pharmaceutical Journal. Switching between weight-loss medications. Available at: https://pharmaceutical-journal.com/article/ld/switching-between-weight-loss-medications

6. NHS Bath and North East Somerset, Swindon and Wiltshire (BSW) ICB. Prescribing guidance for switching tirzepatide to semaglutide. Available at: NHS BSW Prescribing Guidance. This document highlights that there is currently no NICE or MHRA guidance providing direct dose equivalence between tirzepatide and semaglutide.

7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial). New England Journal of Medicine. 2021.

8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Trial). New England Journal of Medicine. 2022.